Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States of America.
Department of Radiology, Division of Interventional Radiology, Massachusetts General Hospital, Boston, MA, United States of America.
Phys Med Biol. 2021 Dec 29;66(24). doi: 10.1088/1361-6560/ac43fd.
. To evaluate the pre-treatment and post-treatment imaging-based dosimetry of patients treated with 90Y-microspheres, including accurate estimations of dose to tumor, healthy liver and lung. To do so, the Monte Carlo (MC) TOPAS platform is in this work extended towards its utilization in radionuclide therapy.. Five patients treated at the Massachusetts General Hospital were selected for this study. All patients had data for both pre-treatment SPECT-CT imaging using 99mTc-MAA as a surrogate of the 90Y-microspheres treatment and SPECT-CT imaging immediately after the 90Y activity administration. Pre- and post-treatment doses were computed with TOPAS using the SPECT images to localize the source positions and the CT images to account for tissue inhomoegeneities. We compared our results with analytical calculations following the voxel-based MIRD scheme.. TOPAS results largely agreed with the MIRD-based calculations in soft tissue regions: the average difference in mean dose to the liver was 0.14 Gy GBq(2.6%). However, dose distributions in the lung differed considerably: absolute differences in mean doses to the lung ranged from 1.2 to 6.3 Gy GBqand relative differences from 153% to 231%. We also found large differences in the intra-hepatic dose distributions between pre- and post-treatment imaging, but only limited differences in the pulmonary dose.. Doses to lung were found to be higher using TOPAS with respect to analytical calculations which may significantly underestimate dose to the lung, suggesting the use of MC methods for 90Y dosimetry. According to our results, pre-treatment imaging may still be representative of dose to lung in these treatments.
. 评估 90Y 微球治疗患者的治疗前后基于成像的剂量学,包括对肿瘤、健康肝脏和肺部剂量的准确估计。为此,在这项工作中,Monte Carlo (MC) TOPAS 平台扩展到用于放射性核素治疗的应用中。.. 选择了在马萨诸塞州综合医院接受治疗的五名患者进行这项研究。所有患者均有 99mTc-MAA 预处理 SPECT-CT 成像(作为 90Y 微球治疗的替代物)和 90Y 活性给药后立即进行的 SPECT-CT 成像的数据。使用 TOPAS 基于 SPECT 图像定位源位置,基于 CT 图像考虑组织不均匀性,计算预处理和后处理剂量。我们将我们的结果与基于体素的 MIRD 方案的分析计算进行了比较。.. TOPAS 结果在软组织区域与基于 MIRD 的计算结果基本一致:肝脏平均剂量的平均差异为 0.14 Gy GBq(2.6%)。然而,肺部的剂量分布差异很大:肺部平均剂量的绝对差异范围为 1.2 至 6.3 Gy GBq,相对差异范围为 153%至 231%。我们还发现治疗前后成像之间肝内剂量分布存在很大差异,但肺部剂量差异有限。.. 使用 TOPAS 计算的肺部剂量高于分析计算,这可能会显著低估肺部剂量,表明使用 MC 方法进行 90Y 剂量学。根据我们的结果,治疗前成像对于这些治疗中的肺部剂量仍然具有代表性。